Ask My Investor AI
Public company · Frankfurt/XetraPublished company research
FRE

The issuer's share page identifies Fresenius SE & Co. KGaA, ticker FRE, main trading location Frankfurt/Xetra, and euro-denominated quotations; the issuer's group overview confirms its headquarters in Bad Homburg, Germany.

Fresenius SE & Co. KGaA

Fresenius Kabi directly supplies generic IV drugs, IV fluids and other products used in critical and chronic care. FY2025 issuer reporting discloses EUR3,735M of Pharma (IV Drugs & Fluids) revenue and EUR813M of Pharma EBIT, demonstrating a financially material operating franchise. The reviewed sources do not isolate essential-medicine economics, shortage-related pricing, capacity utilization or current valuation, so the subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
FRE
Exchange
Frankfurt/Xetra
HQ
Germany
Currency
EUR
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

Fresenius states that Kabi holds leading positions in generic IV drugs and IV fluids in the United States and Europe. Its regulated product portfolio and more than 100 active generic-drug development projects support scale and breadth, but the bounded review did not verify market share, facility-level capacity, inspection status or a resilience premium.

Scarce assets

Scarce assets in this value chain include validated sterile fill-finish lines and aseptic capacity, lyophilization (freeze-drying) capacity, aseptic quality systems and a clean fda inspection/warning-letter record.

Products, segments, and customers

Fresenius Kabi's Pharma (IV Drugs & Fluids) business supplies generic IV drugs and IV fluids, including products for oncology, anesthesia and analgesia, anti-infectives and critical care. The business reported EUR3,735M of FY2025 revenue and EUR813M of EBIT.

Theme capture

Direct capability and financial scale are verified for the broad Pharma (IV Drugs & Fluids) business. The issuer does not separately disclose the share attributable to essential medicines, shortage-prone products, resilience programs or specific US capacity, so theme-specific materiality remains unassessed.

Conditions

What must be true

  1. Pull Fresenius Kabi injectables/IV revenue split and US capacity (e.g., Wilson, NC); confirm current growth and margin; assess share of group value attributable to essential injectables.
  2. The exposure described for Fresenius must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Essential medicine manufacturing resilience brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Injectable and hospital products via Fresenius Kabi (sterile injectables, IV fluids, clinical nutrition)

Essential medicine manufacturing resilience

Direct and financially material at the broad product-line level: Fresenius Kabi's Pharma (IV Drugs & Fluids) business reported EUR3,735M of FY2025 revenue and EUR813M of EBIT. The reviewed disclosure does not isolate essential-medicine, shortage-driven or resilience-specific economics.

Evidence
The FY2025 annual report directly supports the generic-IV-drug and IV-fluid portfolio, Pharma revenue and EBIT, 15 US generic-drug launches and more than 100 active generic-drug development projects. It does not support facility-level US capacity, inspection status, shortage-product mix or a resilience premium.
Materiality
not assessed — The broad Pharma (IV Drugs & Fluids) business is separately disclosed and financially material, but essential-medicine-specific revenue, orders, margins and capacity are not disclosed; theme-specific materiality therefore remains unassessed.
Financial evidence

Official public disclosures

Reference period: FY2025.

  • Fresenius Kabi revenueEUR8,612M
    FY2025[3]
  • Pharma (IV Drugs & Fluids) revenueEUR3,735M
    FY2025[3]
  • Pharma (IV Drugs & Fluids) EBITEUR813M
    FY2025[3]
  • Pharma (IV Drugs & Fluids) EBIT margin21.8%
    FY2025[3]

Limitation: The figures cover the broad Pharma (IV Drugs & Fluids) business and do not isolate essential medicines, shortage-related economics, facility utilization or market-derived valuation.

Risks

Material risks and break conditions

Material risks

  • Procurement failure: GPOs and hospitals may keep rewarding lowest price rather than reliability, so validated capacity earns no durable premium (the primary thesis break).
  • GLP-1 concentration: a meaningful share of West and Stevanato growth is GLP-1-driven (~21-22% of Stevanato revenue); destocking or a shift to oral/alternative delivery could reverse it and blur the essential-medicine signal.

Thesis-break conditions

  • FDA/ASHP active sterile-injectable shortage counts fall sustainably toward pre-2020 lows (roughly sub-50 total active shortages) while procurement tenders remain price-only, indicating reliability is not being rewarded.
  • Aggregate sterile fill-finish and containment capacity additions outpace demand, evidenced by falling capacity utilization and softening pricing/mix at West, Stevanato and Gerresheimer over consecutive quarters.
Investability conclusion

Where the evidence lands

Issuer evidence verifies Fresenius Kabi's direct IV-drug and IV-fluid capability and the financial scale of its broad Pharma business. Essential-medicine-specific economics, facility capacity and current valuation remain unresolved, and no reviewer has accepted the subject; it remains NOT_READY.

Next diligence

  1. Pull Fresenius Kabi injectables/IV revenue split and US capacity (e.g., Wilson, NC); confirm current growth and margin; assess share of group value attributable to essential injectables.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Fresenius share — official issuer listing informationFresenius SE & Co. KGaA · primary · published undated · accessed 2026-07-29
  2. FY2025 annual report — the Group's business modelFresenius SE & Co. KGaA · primary · published 2026 · accessed 2026-07-29
  3. FY2025 annual report — results of operationsFresenius SE & Co. KGaA · primary · published 2026 · accessed 2026-07-29
  4. FY2025 annual report — research and developmentFresenius SE & Co. KGaA · primary · published 2026 · accessed 2026-07-29